Bourgeon Capital Management’s Allogene Therapeutics ALLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $124K | Buy |
+110,000
| New | +$124K | 0.02% | 107 |
|
|
2025
Q1 | – | Sell |
-118,700
| Closed | -$253K | – | 107 |
|
|
2024
Q4 | $253K | Sell |
118,700
-23,880
| -17% | -$50.9K | 0.05% | 110 |
|
|
2024
Q3 | $399K | Buy |
142,580
+10,125
| +8% | +$28.4K | 0.08% | 84 |
|
|
2024
Q2 | $309K | Buy |
132,455
+75,255
| +132% | +$175K | 0.06% | 94 |
|
|
2024
Q1 | $256K | Buy |
57,200
+6,500
| +13% | +$29.1K | 0.05% | 101 |
|
|
2023
Q4 | $163K | Sell |
50,700
-11,000
| -18% | -$35.3K | 0.04% | 109 |
|
|
2023
Q3 | $196K | Sell |
61,700
-5,250
| -8% | -$16.6K | 0.05% | 95 |
|
|
2023
Q2 | $333K | Buy |
66,950
+39,000
| +140% | +$194K | 0.08% | 88 |
|
|
2023
Q1 | $138K | Hold |
27,950
| – | – | 0.03% | 104 |
|
|
2022
Q4 | $176K | Buy |
27,950
+17,000
| +155% | +$107K | 0.04% | 102 |
|
|
2022
Q3 | $118K | Sell |
10,950
-21,050
| -66% | -$227K | 0.03% | 104 |
|
|
2022
Q2 | $365K | Buy |
32,000
+5,500
| +21% | +$62.7K | 0.1% | 76 |
|
|
2022
Q1 | $241K | Buy |
26,500
+20,000
| +308% | +$182K | 0.05% | 90 |
|
|
2021
Q4 | $97K | Sell |
6,500
-25,225
| -80% | -$376K | 0.02% | 124 |
|
|
2021
Q3 | $815K | Sell |
31,725
-1,575
| -5% | -$40.5K | 0.17% | 67 |
|
|
2021
Q2 | $868K | Buy |
+33,300
| New | +$868K | 0.19% | 75 |
|
|
2021
Q1 | – | Sell |
-19,950
| Closed | -$504K | – | 274 |
|
|
2020
Q4 | $504K | Buy |
19,950
+11,350
| +132% | +$287K | 0.12% | 78 |
|
|
2020
Q3 | $324K | Buy |
8,600
+7,600
| +760% | +$286K | 0.1% | 76 |
|
|
2020
Q2 | $43K | Sell |
1,000
-1,250
| -56% | -$53.8K | 0.02% | 125 |
|
|
2020
Q1 | $44K | Buy |
2,250
+1,000
| +80% | +$19.6K | 0.02% | 112 |
|
|
2019
Q4 | $32K | Buy |
+1,250
| New | +$32K | 0.02% | 130 |
|